New drug combo aims to stop breast Cancer's second strike
NCT ID NCT07190443
Summary
This study is for people whose hormone-positive, HER2-negative breast cancer has returned in the breast or nearby lymph nodes after initial treatment. It tests if adding a drug called abemaciclib to standard hormone therapy is better at preventing the cancer from coming back or spreading than hormone therapy alone. About 290 participants will be randomly assigned to receive one of the two treatment plans for two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.